Rose PG - Search Results

1

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP. Fracasso PM, et al. Among authors: rose pg. J Clin Oncol. 2001 Jun 15;19(12):2975-82. doi: 10.1200/JCO.2001.19.12.2975. J Clin Oncol. 2001. PMID: 11408492 Clinical Trial.

2

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.

Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J. Kemp G, et al. J Clin Oncol. 1996 Jul;14(7):2101-12. doi: 10.1200/JCO.1996.14.7.2101. J Clin Oncol. 1996. PMID: 8683243 Clinical Trial.

3

Phase II evaluation of altretamine for advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.

Rose PG, Blessing JA, Arseneau J. Rose PG, et al. Gynecol Oncol. 1996 Jul;62(1):100-2. doi: 10.1006/gyno.1996.0196. Gynecol Oncol. 1996. PMID: 8690279 Clinical Trial.

4

A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

Rose PG, Blessing JA, Lewandowski GS, Creasman WT, Webster KD. Rose PG, et al. Gynecol Oncol. 1996 Oct;63(1):101-4. doi: 10.1006/gyno.1996.0286. Gynecol Oncol. 1996. PMID: 8898177 Clinical Trial.

5

A phase II trial of edatrexate in previously treated squamous cell cervical cancer: a Gynecologic Oncology Group study.

Broun ER, Iseminger KA, Rose PG, Lentz SL, Malfetano JH, Lincoln S, Mannel R. Broun ER, et al. Among authors: rose pg. Am J Clin Oncol. 1997 Feb;20(1):78-80. doi: 10.1097/00000421-199702000-00017. Am J Clin Oncol. 1997. PMID: 9020294 Clinical Trial.

6

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

Rose PG, Blessing JA, Mayer AR, Homesley HD. Rose PG, et al. J Clin Oncol. 1998 Feb;16(2):405-10. doi: 10.1200/JCO.1998.16.2.405. J Clin Oncol. 1998. PMID: 9469322 Clinical Trial.

7

Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.

Rose PG, Fusco N, Fluellen L, Rodriguez M. Rose PG, et al. J Clin Oncol. 1998 Apr;16(4):1494-7. doi: 10.1200/JCO.1998.16.4.1494. J Clin Oncol. 1998. PMID: 9552057

8

Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.

Markman M, Rose PG, Jones E, Horowitz IR, Kennedy A, Webster K, Belinson J, Fusco N, Fluellen L, Kulp B, Peterson G, McGuire WP. Markman M, et al. Among authors: rose pg. J Clin Oncol. 1998 May;16(5):1849-51. doi: 10.1200/JCO.1998.16.5.1849. J Clin Oncol. 1998. PMID: 9586900 Clinical Trial.

9

Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.

Rose PG, Blessing JA, Van Le L, Waggoner S. Rose PG, et al. Gynecol Oncol. 1998 Aug;70(2):263-6. doi: 10.1006/gyno.1998.5097. Gynecol Oncol. 1998. PMID: 9740702 Clinical Trial.

10

Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.

Rose PG, Blessing JA, Soper JT, Barter JF. Rose PG, et al. Gynecol Oncol. 1998 Aug;70(2):267-71. doi: 10.1006/gyno.1998.5080. Gynecol Oncol. 1998. PMID: 9740703 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

327 results

Search Page

Filters